ClearTrial today unveiled the ClearTrial Study Costing & Optimization Service (SCOS), a service that provides greater visibility and control over clinical trial costs, resources, and timelines for smaller biopharma companies. The ClearTrial SCOS delivers a combination of ClearTrial software and ClearTrial’s Clinical Services personnel to bring greater speed and accuracy to clinical trial planning.
"Many smaller biopharma companies lack the visibility to accurately forecast clinical trials, leading to them not understanding how much clinical trials should really cost, as well as dealing with unforeseen shifts in trial timelines," noted Andrew Grygiel, Vice President of Marketing and Product Management for ClearTrial.
During the ClearTrial SCOS, a ClearTrial Clinical Services Manager (CSM) acts as an extension of a company's internal clinical team. The ClearTrial CSM works with that team to fully understand the study's design, objectives, and clinical assumptions, then leverages the industry intelligence and activity-based planning methodology of the ClearTrial software to generate detailed and accurate cost, resource, and timeline reports for multiple study scenarios. These scenarios enable the ClearTrial CSM and the company's team to perform "what-if" analyses for cutting cost, time, or both from a study.
"As the cost and timeline pressures continue to grow, organizations large and small must ensure that their clinical trial dollars are being spent as effectively as possible," stated ClearTrial CEO Mike Soenen. "We're pleased to be able to help our industry achieve this goal by introducing the ClearTrial Study Costing & Optimization Service to the market."
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.